Cargando…

Effect of various drugs used in conservative therapy of hepatorenal syndrome: A retrospective drug utilization study

OBJECTIVES: To analyze the impact of various drugs used in conservative therapy on renal failure and mortality in hepatorenal syndrome (HRS) at a tertiary care teaching hospital. MATERIALS AND METHODS: Retrospective review of hospital admission records was conducted for case records with HRS as diag...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hiremath, Sharanabasayyaswamy B., Kamdod, Mohammed Ameeruddin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Medknow Publications & Media Pvt Ltd 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175892/ https://www.ncbi.nlm.nih.gov/pubmed/25298585 http://dx.doi.org/10.4103/0253-7613.140590

Ejemplares similares

Survival benefits of terlipressin and non-responder state in hepatorenal syndrome: A meta-analysis
por: Hiremath, Sharanabasayyaswamy B., et al.
Publicado: (2013)

CONFIRMing Hepatorenal Syndrome Management: #NephJC Editorial
por: Willows, Jamie, et al.
Publicado: (2021)

Hepatorenal Syndrome
por: Kiser, Tyree H.
Publicado: (2014)

Hepatorenal syndrome: Update on diagnosis and therapy
por: Acevedo, Juan G, et al.
Publicado: (2017)

Terlipressin for the Prevention and Treatment of Renal Decline in Hepatorenal Syndrome: A Drug Profile
por: Ayyad, Ahlam, et al.
Publicado: (2023)

Responsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1
por: Velez, Juan Carlos Q., et al.
Publicado: (2023)

Hepatorenal Syndrome: Outcome of Response to Therapy and Predictors of Survival
por: Heidemann, Jan, et al.
Publicado: (2015)

Metabolic syndrome and the hepatorenal reflex
por: Wider, Michael D.
Publicado: (2016)

Metabolic syndrome and the hepatorenal reflex
por: Wider, Michael D.
Publicado: (2016)

A Review of Hepatorenal Syndrome
por: Subedi, Abinash, et al.
Publicado: (2021)

COVID-19 and hepatorenal syndrome
por: Wu, Henry H L, et al.
Publicado: (2022)

The Hepatorenal Syndrome Patient Pathway: Retrospective Analysis of Electronic Health Records
por: Jamil, Khurram, et al.
Publicado: (2022)

The Effect of Terlipressin on Renal Replacement Therapy in Patients with Hepatorenal Syndrome
por: Velez, Juan Carlos Q., et al.
Publicado: (2023)

Hepatorenal Syndrome: Aetiology, Diagnosis, and Treatment
por: Low, G., et al.
Publicado: (2015)

Commentary: Metabolic syndrome and the hepatorenal reflex
por: Wider, Michael D.
Publicado: (2016)

Erratum: Metabolic syndrome and the hepatorenal reflex
Publicado: (2017)

Hepatorenal syndrome in children: a review
por: Liu, Priscila Menezes Ferri, et al.
Publicado: (2020)

Management of Hepatorenal Syndrome: A Review
por: Tariq, Raseen, et al.
Publicado: (2020)

Liver Kidney Crosstalk: Hepatorenal Syndrome
por: Nassar, Mahmoud, et al.
Publicado: (2021)

Impact of Palliative Care Services on Treatment and Resource Utilization for Hepatorenal Syndrome in the United States
por: Thongprayoon, Charat, et al.
Publicado: (2021)

Hepatorenal tyrosinemia
por: KITAGAWA, Teruo
Publicado: (2012)

Prognostic Markers in Patients with Ascites and Hepatorenal Syndrome
por: Nazal, Leyla, et al.
Publicado: (2011)

Optimal management of hepatorenal syndrome in patients with cirrhosis
por: Angeli, Paolo, et al.
Publicado: (2010)

Combined Liver-Kidney Transplantation for Hepatorenal Syndrome
por: Kanubhai Sutariya, V., et al.
Publicado: (2015)

Acute kidney injury and hepatorenal syndrome in cirrhosis
por: Gupta, Kapil, et al.
Publicado: (2021)

Recent advances in the understanding and management of hepatorenal syndrome
por: Simbrunner, Benedikt, et al.
Publicado: (2021)

Invasive hemodynamic parameters in patients with hepatorenal syndrome
por: Pelayo, Jerald, et al.
Publicado: (2022)

Hepatorenal syndrome: Current concepts and future perspectives
por: Jung, Chan-Young, et al.
Publicado: (2023)

An investigation of reconstituted terlipressin infusion stability for use in hepatorenal syndrome
por: Bui, Thi Ngoc Nhieu, et al.
Publicado: (2020)

Effect of calcium on anxiolytic activity of diazepam and verapamil in rats
por: Hiremath, Sharanabasayyaswamy B., et al.
Publicado: (2010)

Markers of cell death predict therapy response in patients with cirrhosis and hepatorenal syndrome
por: Heinrich, Sophia, et al.
Publicado: (2022)

Cost-Utility Analysis of Vasoconstrictors Plus Albumin in the Treatment of Thai Patients with Type 1 Hepatorenal Syndrome
por: Sangroongruangsri, Sermsiri, et al.
Publicado: (2021)

Hepatorenal syndrome: one size does not fit all
por: Parikh, Amay, et al.
Publicado: (2012)

Hepatorenal syndrome:Response to terlipressin and albumin and its determinants
por: Sarwar, Shahid, et al.
Publicado: (2016)

Good Enough? Terlipressin, Hepatorenal Syndrome, and the Usage of RRT
por: Belcher, Justin M.
Publicado: (2023)

Following the MAP for Improved Kidney Function in Hepatorenal Syndrome
por: Thau, Matthew R., et al.
Publicado: (2023)

Treatment and outcome of hepatorenal syndrome in Japan: a retrospective cohort study using a national inpatient database
por: Okushin, Kazuya, et al.
Publicado: (2023)

Development and validation of a prognostic model for patients with hepatorenal syndrome: A retrospective cohort study
por: Sheng, Xin-Yu, et al.
Publicado: (2021)

A Systematic Review of the Emerging Treatment for Hepatorenal Syndrome With a Principal Focus on Terlipressin: A Recent FDA-Approved Drug
por: Thangaraj, Santhosh Raja, et al.
Publicado: (2023)

Renal blood flow in cirrhotic patients and hepatorenal syndrome (HRS)
por: Nagi, HK, et al.
Publicado: (2002)

Cannot write session to /tmp/vufind_sessions/sess_acro89lusl5lr4q1jkri98o7qu